New drug combo shows promise for newly diagnosed blood cancer patients

A major clinical trial found that daratumumab combined with lenalidomide and dexamethasone improved outcomes for multiple myeloma patients at initial diagnosis. The results could reshape treatment protocols and expand the addressable market for these therapies across oncology practices and hospital systems.

Originaltitel: Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma